Introduction And Epidemiology
- Most common primary malignant renal tumor of childhood.
- Represents sixth most common childhood malignancy; accounts for 6% of pediatric malignancies.
- Accounts for >95% of childhood kidney tumors.
- Peak incidence occurs between 2-3 years of age.
- 75% of cases diagnosed in children <5 years old.
- Median age at presentation: 44 months for unilateral disease, 32 months for bilateral disease.
- Bilateral involvement occurs in 7% of cases; multicentricity seen in 11%.
- Gender distribution: Male-to-female ratio 0.92:1 (unilateral) and 0.6:1 (bilateral).
- Ethnic variation: Asian children exhibit approximately half the incidence rates of White and Black children.
Genetics And Pathophysiology
- Derived from incompletely differentiated renal mesenchyme.
- Nephrogenic rests (foci of benign, undifferentiated mesenchyme) persist abnormally and serve as precursor lesions.
- Nephrogenic rests found in 1% of general population but up to 90% of children with bilateral Wilms or associated syndromes.
- WT1 gene (11p13): Encodes zinc finger transcription factor; mutated or deleted in 10-15% of tumors.
- WT2 locus (11p15.5): Contains cluster of imprinted genes (IGF2, H19, CDKN1C, KCNQ10T1). Epigenetic alterations (loss of imprinting) result in biallelic expression of IGF2.
- Wnt signaling pathway mutations: CTNNB1 (15%) and WTX (20%).
- miRNA processing gene mutations: DROSHA (10%), DICER1, DGCR8, XPO5, TARBP2 altered in 20-30% of tumors.
- TP53 mutations: Observed in 5% of tumors; strongly associated with anaplastic histology.
- SIX1 and SIX2 mutations: Alter progenitor proliferation.
Associated Congenital Syndromes
| Syndrome | Genetic Lesion | Clinical Phenotype | Estimated Wilms Tumor Risk |
|---|---|---|---|
| WAGR Syndrome | 11p13 deletion (WT1 and PAX6) | Wilms tumor, aniridia, genitourinary anomalies, delayed-onset renal failure, mental retardation. | 45-57%. |
| Denys-Drash Syndrome | WT1 missense mutation (exon 8/9) | Ambiguous genitalia, pseudohermaphroditism, diffuse mesangial sclerosis, early renal failure. | ~75% (>70%). |
| Beckwith-Wiedemann Syndrome | 11p15.5 epigenetic alterations (WT2) | Hemihypertrophy, macroglossia, omphalocele, organomegaly, neonatal hypoglycemia. | ~5%. |
| Frasier Syndrome | WT1 mutation (intron 9 splice site) | Ambiguous genitalia, streak gonads, focal segmental glomerulosclerosis. | 8%. |
| Perlman Syndrome | DIS3L2 mutation | Fetal macrosomia, renal dysplasia, multiple congenital anomalies. | 64%. |
| Simpson-Golabi-Behmel | GPC3 (Xq26) | Overgrowth, coarse facial features. | 10%. |
[Data derived from congenital anomalies and Wilms tumor associations].
Pathology And Histologic Classification
- Classic Triphasic Morphology: Composed of blastemal, stromal, and epithelial cells mimicking normal renal embryogenesis.
- Favorable Histology (FH): Absence of anaplastic features.
- Unfavorable Histology (Anaplasia): Characterized by extreme nuclear pleomorphism, nuclear enlargement, and irregular mitotic figures.
- Focal Anaplasia: Anaplastic cells strictly confined within a single region.
- Diffuse Anaplasia: Anaplastic cells in extrarenal sites, random biopsies, or multiple slides. Carries significantly worse prognosis.
Clinical Manifestations
- Abdominal Mass: Most common presentation (75-80%). Firm, non-tender, smooth mass rarely crossing midline.
- Abdominal Pain: Occurs in 28-30% of patients; typically follows trauma-induced intra-tumoral hemorrhage.
- Hypertension: Present in 25-26%; attributed to tumor-induced increased renin activity.
- Hematuria: Gross hematuria in 18%; microscopic hematuria in 24%.
- Constitutional Symptoms: Fever (20-22%), anorexia, vomiting, weight loss.
- Vascular Involvement: Tumor thrombus extends into inferior vena cava (IVC) in 4-10% of cases; rarely reaches right atrium. Poses fatal pulmonary embolism risk.
- Hematologic Derangements: Polycythemia (elevated erythropoietin), thrombocytosis, acquired von Willebrand disease (4% incidence), acquired Factor VII deficiency.
Diagnostic Evaluation
- Ultrasonography (US): Initial modality. Differentiates solid from cystic masses. Doppler imaging assesses renal veins and IVC for tumor thrombus.
- Computed Tomography (CT): Abdominal CT defines disease extent, assesses contralateral kidney, and identifies liver metastasis/lymphadenopathy. Chest CT essential for detecting pulmonary metastasis.
- Magnetic Resonance Imaging (MRI): Useful for delineating extensive IVC/atrial thrombus or distinguishing Wilms tumor from nephrogenic rests.
- Biopsy: Generally discouraged to avoid capsular rupture and subsequent tumor upstaging (COG approach). Indicated for atypical presentations (age >10 years, inflammation, unresectable tumors).
- Screening Protocols: Children with high-risk syndromes (WAGR, Denys-Drash, Beckwith-Wiedemann) require routine screening abdominal ultrasounds every 3 months until age 5-8.
Staging Classification (Children's Oncology Group)
| Stage | Pathologic And Surgical Criteria |
|---|---|
| Stage I | Tumor confined to kidney. Completely resected with negative margins. Renal capsule intact. No prior biopsy or rupture. Regional lymph nodes negative. |
| Stage II | Tumor extends beyond kidney but completely resected with negative margins and nodes. Includes penetration of renal capsule or invasion of renal sinus vessels. |
| Stage III | Residual tumor confined to abdomen. Includes gross/microscopic residual, preoperative/intraoperative spillage, prior biopsy, positive regional lymph nodes, or peritoneal implants. |
| Stage IV | Hematogenous metastases (lung, liver, bone, brain) or lymph node metastases outside abdominopelvic region. |
| Stage V | Bilateral renal involvement at time of initial diagnosis. |
Prognostic Factors
- Favorable Predictors: Young age (<24 months), low tumor weight (<550 g), low stage, favorable histology.
- Adverse Predictors:
- Diffuse anaplasia (associated with TP53 mutations).
- Loss of heterozygosity (LOH) at chromosomes 1p and 16q (associated with inferior relapse-free and overall survival).
- Gain of chromosome 1q (independent predictor of inferior survival).
- Incomplete lung nodule response after 6 weeks of chemotherapy.
Management Strategies
Surgical Approach
- Children's Oncology Group (COG) Paradigm: Recommends upfront radical nephrectomy and thorough lymph node sampling prior to chemotherapy. Facilitates accurate histological diagnosis and risk-adapted staging.
- International Society of Pediatric Oncology (SIOP) Paradigm: Recommends preoperative chemotherapy without prior biopsy to shrink tumor, followed by surgery.
- Inoperable Or Bilateral Tumors: Preoperative chemotherapy (Vincristine, Actinomycin D, Doxorubicin) administered for 6 weeks. Followed by definitive surgery (renal-sparing partial nephrectomy preferred for bilateral disease).
Risk-Adapted Chemotherapy Regimens
| Risk Category | Chemotherapy Regimen | Duration |
|---|---|---|
| Very Low Risk (Stage I FH, <24 months, <550g) | Nephrectomy alone (Observation) | N/A |
| Stage I & II FH (No LOH) | Regimen EE4A: Vincristine + Actinomycin D | 18 weeks |
| Stage III FH (No LOH) | Regimen DD4A: Vincristine + Actinomycin D + Doxorubicin | 24 weeks |
| Stage I-III FH with LOH 1p/16q | Regimen DD4A (Stage I/II) or Regimen M (Stage III) | 24-31 weeks |
| Stage IV FH | Regimen DD4A (Rapid lung responders) or Regimen M (Slow responders/LOH) | 24-31 weeks |
| Diffuse Anaplasia (Stage II-IV) | Regimen UH-1 / UH-2: Vincristine, Doxorubicin, Cyclophosphamide, Carboplatin, Etoposide (+ Irinotecan) | 30-36 weeks |
[Data synthesized from COG clinical trial protocols].
Radiation Therapy
- Specifically omitted for Stage I and II Favorable Histology Wilms tumor.
- Flank/Tumor Bed Irradiation: Indicated for Stage III FH (1080 cGy) and all stages with focal/diffuse anaplasia (up to 1980 cGy for diffuse anaplasia).
- Whole-Abdominal Irradiation: Indicated for gross tumor spillage, peritoneal seeding, or diffuse intraperitoneal rupture (1050 cGy).
- Whole-Lung Irradiation: Indicated for metastatic pulmonary disease (1200 cGy; reduced to 1050 cGy if <12 months old). May be omitted if rapid complete response achieved with initial chemotherapy.
- Preoperative chemotherapy for bilateral Wilms tumor does not constitute an independent indication for radiotherapy unless positive margins persist post-surgery.
Relapse And Late Effects
- Recurrence: Occurs in ~15% of favorable-histology and 50% of anaplastic tumors. Most relapses manifest within 2 years of diagnosis.
- Salvage Therapy: Agents include Ifosfamide, Carboplatin, Etoposide (ICE), Topotecan, and Irinotecan. High-dose chemotherapy with autologous stem cell rescue considered for very high-risk relapse.
- Overall Survival: Exceeds 90% with modern multimodal therapy.
- Late Complications: Survivors face significant risks including doxorubicin-induced cardiotoxicity, radiation-induced pulmonary toxicity, progressive renal failure, fertility impairment (secondary to alkylating agents or pelvic radiation), and secondary malignant neoplasms. Long-term surveillance remains essential.